Effects of Atorvastatin 10 mg Versus 40 mg in Eight Months Follow-up Coronary Flow Reserve and Bone Marrow Stem Cell Mobilization in Patients With Acute Myocardial Infarction

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Many data indicate that statins increase mobilization of bone marrow-derived stem cells, and circulating bone marrow-derived stem cells are capable of homing to sites of myocardial infarction and endothelial disruption, thereby restoring myocardial function and microvascular integrity after acute myocardial infarction. Atorvastatin is widely used in the treatment of hyperlipidemia, especially after acute myocardial infarction. High-dose atorvastatin has been known to stop the progression of atherosclerosis and to decrease the levels of inflammatory markers.

The purpose of this prospective, randomized, single-blinded trial is to compare the effect of atorvastatin 10 mg versus 40 mg in restoring coronary flow reserve (CFR) and in serial bone marrow stem cell mobilization during the 8 months follow-up in patients with acute myocardial infarction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Korea University Anam Hospital
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Age 18 years and above

• Gender eligible for study both

• Patients with acute myocardial infarction requiring sirolimus-eluting stent implantation

• Acute myocardial infarction affecting proximal to mid coronary arteries

• No lesions greater than 50 percent diameter stenosis distal to the stent implantation

• Patients with informed consent

Exclusion Criteria:

• Left main lesion

• Killip Class IV acute myocardial infarction

• Patients with current use of any statin

• Tortuous lesion with difficult intracoronary Doppler wiring

• Acute myocardial infarction affecting distal coronary arteries

• Acute myocardial infarction affecting branching coronary arteries

• The use of thiazolidinediones within 3 months

• Previous history of PCI or bypass surgery on infarct-related coronary artery

• Patients with any contraindications to the treatment of atorvastatin

• Pregnant or lactating patients

• Chronic alcohol or drug abuse

• Hepatic dysfunction (3 times above upper normal limit 5 days after AMI)

• Renal dysfunction (Creatinine greater than 2.0 mg/dL)

• Severe Heart failure (EF less than 25 percent)

• Expected life expectancy of less thna 1 year